NSC 74859 (Synonyms: S3I-201)

Name: NSC 74859
Brand: MedChemExpress
SKU: HY-15146
Rating: 5.0 (61 reviews)

製品番号: HY-15146 純度: 98.35%: Data Sheet SDS COA 取扱説明書
FAQs
Technical Support

NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC₅₀ of 86 μM.

商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。

CAS 番号 : 501919-59-1

容量	価格（税別）	在庫状況	数量
>無料サンプル (0.1 - 0.2 mg)		今すぐ申し込む
5 mg	$61	在庫あり	Estimated Time of Arrival: December 31
10 mg	$77	在庫あり	Estimated Time of Arrival: December 31
25 mg	$135	在庫あり	Estimated Time of Arrival: December 31
50 mg	$193	在庫あり	Estimated Time of Arrival: December 31
100 mg	$363	在庫あり	Estimated Time of Arrival: December 31
200 mg		お問い合わせ
500 mg		お問い合わせ

or バルクお問い合わせ

* アイテムを追加する前、数量をご選択ください

This product is a controlled substance and not for sale in your territory.

カスタマーレビュー

Based on 61 publication(s) in Google Scholar

顧客検証

: NSC 74859 purchased from MedChemExpress. Usage Cited in: J Exp Clin Cancer Res. 2023 Feb 27;42(1):51. [Abstract]; The enhanced phosphorylation level of JAK2 and STAT3 mediated by rhCCL18 can be reversed by NSC 74859 (S3I-201) in EC-109, EC-109 Vector and EC-109 shPITPNM3 cells.

: NSC 74859 purchased from MedChemExpress. Usage Cited in: Cancer Lett. 2018 Aug 28:430:201-214. [Abstract]; CD146^WT or CD146^KO MEFs are stimulated with or without TGF-β1 (10 ng/mL) for 24 h in the presence or absence of NSC74859 (200 μM). The expression of CD146, the expression and activation of STAT3, and the expression levels of E-cadherin, N-cadherin, and Twist are assessed by immunoblotting.

: NSC 74859 purchased from MedChemExpress. Usage Cited in: Biofactors. 2018 Nov;44(6):570-576. [Abstract]; Westen Blot analysis of HMGB1 expression in HepG2 cells in the treatment of Stat3 inhibitor NSC74859 (SI3), or activator (NAC).

: NSC 74859 purchased from MedChemExpress. Usage Cited in: J Cell Biochem. 2019 Feb;120(2):1878-1893. [Abstract]; AA-FLS are treated with different concentrations (25, 50, and 100 µM) of Ferulic acid (FA) and 50 µM of S3I-201 and then cultured in the presence or absence of IL-17 (10 ng/mL). The cell lysates are subjected to Western blot analysis to assess the expression levels of TLR-3, Cyr61, IL-23 and GM-CSF proteins.

: NSC 74859 purchased from MedChemExpress. Usage Cited in: Mol Immunol. 2017 Nov:91:134-144. [Abstract]; AA-FLS cultured in the presence or absence of S3I-201 for 24 h, then treated with IL-17 for an additional 24 h and phosphorylation of STAT-3 is detected by western blotting.

STAT アイソフォーム固有の製品をすべて表示:

すべてのアイソフォームを表示

STAT3 STAT5 STAT6 STAT1

生物活性
プロトコル
純度とドキュメンテーション
参考文献
カスタマーレビュー

製品説明

NSC 74859 (S3I-201) is a selective Stat3 inhibitor with an IC₅₀ of 86 μM^[1].

IC₅₀ & Target^[1]

STAT3

86 μM (IC₅₀)

Cellular Effect

Cell Line	Type	Value	Description	References
NIH3T3	IC₅₀	> 300 3 Compound: 21, S3I-201	Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	>300 3 Compound: 21, S3I-201	Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	160 3 Compound: 21, S3I-201	Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	160 3 Compound: 21, S3I-201	Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	86 3 Compound: 21, S3I-201	Inhibition of STAT3 dimerization in v-Src transformed mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction in nucleus after 30 mins by EMSA Inhibition of STAT3 dimerization in v-Src transformed mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction in nucleus after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	>300 3 Compound: S3I-201, NSC-74859	Inhibition of Stat1:Stat1 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat1:Stat1 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	160 3 Compound: S3I-201, NSC-74859	Inhibition of Stat1:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat1:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	86 3 Compound: 21, S3I-201	Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	86 3 Compound: 21, S3I-201	Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	160 3 Compound: 21, S3I-201	Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT1/STAT3 in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1/STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	86 3 Compound: S3I-201, NSC-74859	Inhibition of Stat3 DNA binding activity in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat3 DNA binding activity in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	160 3 Compound: S3I-201, NSC-74859	Inhibition of Stat1:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat1:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	166 3 Compound: S3I-201, NSC-74859	Inhibition of Stat5:Stat5 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat5:Stat5 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	166 3 Compound: S3I-201, NSC-74859	Inhibition of Stat5:Stat5 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat5:Stat5 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	86 3 Compound: 21, S3I-201	Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA Inhibition of STAT3 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	86 3 Compound: 21, S3I-201	Inhibition of STAT3 dimerization in v-Src transformed mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction in nucleus after 30 mins by EMSA Inhibition of STAT3 dimerization in v-Src transformed mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT3-DNA interaction in nucleus after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	86 3 Compound: S3I-201, NSC-74859	Inhibition of Stat3 DNA binding activity in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat3 DNA binding activity in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	86 3 Compound: S3I-201, NSC-74859	Inhibition of Stat3:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat3:Stat3 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]
NIH3T3	IC₅₀	> 300 3 Compound: 21, S3I-201	Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA Inhibition of STAT1 dimerization in EGF-stimulated mouse NIH/3T3 cells overexpressing human EGFR assessed as suppression of STAT1-DNA interaction after 30 mins by EMSA	[PMID: 22650325]
NIH3T3	IC₅₀	> 300 3 Compound: S3I-201, NSC-74859	Inhibition of Stat1:Stat1 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5 Inhibition of Stat1:Stat1 dimerization in EGF-stimulated mouse NIH3T3 cells expressing hEGFR with activated Stat1, Stat3, Stat5	[PMID: 17463090]

体外実験

NSC 74859 (S3I-201) preferentially inhibits Stat3 DNA-binding activity over that of Stat1 (IC₅₀ values, Stat3?Stat3, 86±33 μM; Stat1?Stat3, 160±43 μM; and Stat1?Stat1, >300 μM) and inhibits that of Stat5 with IC₅₀ of 166±17 μM). NSC 74859 significantly reduces viable cell numbers and inhibits growth of transformed mouse fibroblasts NIH 3T3/v-Src and breast carcinoma cell lines (MDA-MB-231, MDA-MB-435, and MDA-MB-468). At 30-100 μM, NSC 74859 induces significant apoptosis in the representative human breast carcinoma cell line MDA-MB-435 and NIH 3T3/v-Src, both of which harbor constitutively active Stat3. The breast carcinoma MDA-MB-435 cell line is more sensitive to 30 μM NSC 74859. By contrast, the human breast cancer MDA-MB-453 cells and the normal mouse fibroblasts (NIH 3T3), which do not contain abnormal Stat3 activity, are less sensitive to NSC 74859 at 100 μM or less. At 300 μM or higher, NSC 74859 induced general, nonspecific cytotoxicity independent of Stat3 activation status^[1]. Huh-7 cells do not express β2SP or TBGFR2 and are sensitive to STAT3 inhibition, with an IC₅₀ of 100 μM for NSC 74859, regardless of CD133⁺ status. The IC₅₀ of NSC 74859 is 150 μM for Huh-7 and SNU-398 cells, 15 μM for SNU-475 cells and 200 μM for SNU-182 cells. NSC 74859 inhibits breast carcinoma MDA-MB-435, MDA-MB-453 and MDA-MB-231 cell lines with an IC₅₀ close to 100 μM^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

体内実験

Human breast (MDA-MB-231) tumor-bearing mice are given an i.v. injection of NSC 74859 (S3I-201) or vehicle every 2 or every 3 days for 2 weeks, and tumor measurements are taken every 2-3 days. Compared with control (vehicle-treated) tumors, which continued to grow, human breast tumors in mice that received S3I-201 display strong growth inhibition. Continued evaluation of treated mice on termination of treatment shows no resumption of tumor growth, suggesting potentially a long-lasting effect of S3I-201 on tumor growth^[1]. Compared with vehicle-treated control tumors (n=15), which continued to grow, S3I-201 treatment of somatotroph tumor xenografts (n=15) significantly attenuated tumor growth for the duration of the experiment. Tumors derived from NSC 74859-treated rats are significantly smaller than those from the untreated group (220±16 mm³ vs. 287±16 mm³, P<0.01) as early as 5 days after NSC 74859 injection. Fifteen days after treatments, the average tumor volume of NSC 74859-treated rats is 64% of that of controls (449±40 mm³ vs. 708±83 mm³, P<0.01). Rats are sacrificed and tumors are harvested 15 days after treatment initiation. The average tumor weight of NSC 74859-treated rats is 78±8 mg, while tumors derived from control rats weighed 114±13 mg (32% reduction; P<0.05)^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

分子量

365.36

分子式

C₁₆H₁₅NO₇S

CAS 番号

501919-59-1

Appearance

Solid

Color

White to gray

SMILES

OC1=CC(NC(COS(=O)(C2=CC=C(C=C2)C)=O)=O)=CC=C1C(O)=O

輸送条件

Room temperature in continental US; may vary elsewhere.

保管条件

Powder	-20°C	3 years
	4°C	2 years
* The compound is unstable in solutions, freshly prepared is recommended.

溶剤 & 溶解度

体外:

DMSO : 100 mg/mL (273.70 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.7370 mL	13.6851 mL	27.3703 mL
5 mM	0.5474 mL	2.7370 mL	5.4741 mL
10 mM	0.2737 mL	1.3685 mL	2.7370 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）

体積 _（開始）

濃度 _（終了）

体積 _（終了）

体内:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 7.5 mg/mL (20.53 mM); Clear solution

This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 7.5 mg/mL (20.53 mM); Clear solution

This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 7.5 mg/mL (20.53 mM); Clear solution

This protocol yields a clear solution of ≥ 7.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (75.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline
Solubility: ≥ 2.5 mg/mL (6.84 mM); Clear solution
Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (6.84 mM); Clear solution

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*The compound is unstable in solutions, freshly prepared is recommended.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

純度とドキュメンテーション

純度: 98.35%

Select Batch:

データシート (280 KB) SDS (393 KB)

COA (247 KB) HNMR (134 KB) LCMS (103 KB)

取扱説明書 (2659 KB)

参考文献

[1]. Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. [Content Brief]

[2]. Lin L, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene. 2009 Feb 19;28(7):961-72. [Content Brief]

[3]. Zhou C, et al. STAT3 upregulation in pituitary somatotroph adenomas induces hypersecretion. J Clin Invest. 2015 Apr;125(4):1692-702 [Content Brief]

細胞実験 ^[1]	Proliferating cells are treated with or without NSC 74859 (30-100 μM) for up to 48 h. In some cases, cells are first transfected with Stat3C, ST3-NT, or ST3-SH2 domain or mock-transfected for 24 h before treatment with compound for an additional 24-48 h. Cells are then detached and analyzed by annexin V binding and flow cytometry to quantify the percent apoptosis^[1]. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
動物実験 ^[1]^[3]	Mice^[1] Six-week-old female athymic nude mice are used. Athymic nude mice are injected in the left flank area s.c. with 5×10⁶ human breast cancer MDA-MB-231 cells in 100 μL of PBS. After 5-10 days, tumors with a diameter of 3 mm are established. Animals are given NSC 74859 i.v. at 5 mg/kg every 2 or 3 days for 2 weeks and monitored every 2 or 3 days. Animals are stratified so that the mean tumor sizes in all treatment are nearly identical. Tumor volume is calculated according to the formula V=0.52×a²×b, where a is the smallest superficial diameter and b is the largest superficial diameter. Rats^[3] Four-week-old female Wistar Furth rats are used. GH3 cells (5×10⁵ cells in 100 μL Matrigel) are subcutaneously injected into the left lumbar area. After 7 days, tumors with a volume of approximately 100 mm³ are established. Rats are given NSC 74859 intravenously at 5 mg/kg every 2 or 3 days for 2 weeks. Tumor size is measured by caliper measurements twice a week, and volume is calculated as follows: volume=(length×width²)/2. Three weeks after cell inoculations, animals are euthanized and excised tumors are weighed. Blood samples are collected 1 day before S3I-201 treatment and again on the day of euthanization. Serum GH and prolactin are assessed by RIA or ELISA, respectively. MedChemExpress (MCE) はこれらの方法の精度を確認していません。こちらは参照専用です。
参考文献	[1]. Siddiquee K, et al. Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc Natl Acad Sci U S A. 2007 May 1;104(18):7391-6. [Content Brief] [2]. Lin L, et al. The STAT3 inhibitor NSC 74859 is effective in hepatocellular cancers with disrupted TGF-β signaling. Oncogene. 2009 Feb 19;28(7):961-72. [Content Brief] [3]. Zhou C, et al. STAT3 upregulation in pituitary somatotroph adenomas induces hypersecretion. J Clin Invest. 2015 Apr;125(4):1692-702 [Content Brief]

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. The compound is unstable in solutions, freshly prepared is recommended.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.7370 mL	13.6851 mL	27.3703 mL	68.4257 mL
	5 mM	0.5474 mL	2.7370 mL	5.4741 mL	13.6851 mL
	10 mM	0.2737 mL	1.3685 mL	2.7370 mL	6.8426 mL
	15 mM	0.1825 mL	0.9123 mL	1.8247 mL	4.5617 mL
	20 mM	0.1369 mL	0.6843 mL	1.3685 mL	3.4213 mL
	25 mM	0.1095 mL	0.5474 mL	1.0948 mL	2.7370 mL
	30 mM	0.0912 mL	0.4562 mL	0.9123 mL	2.2809 mL
	40 mM	0.0684 mL	0.3421 mL	0.6843 mL	1.7106 mL
	50 mM	0.0547 mL	0.2737 mL	0.5474 mL	1.3685 mL
	60 mM	0.0456 mL	0.2281 mL	0.4562 mL	1.1404 mL
	80 mM	0.0342 mL	0.1711 mL	0.3421 mL	0.8553 mL
	100 mM	0.0274 mL	0.1369 mL	0.2737 mL	0.6843 mL

NSC 74859 Related Classifications

Molarity Calculator
Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

質量		濃度		体積		分子量 *
	=		×		×

The dilution calculator equation

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

一般には略語で表示されます：C₁V₁ = C₂V₂

濃度 _（開始）	×	体積 _（開始）	=	濃度 _（終了）	×	体積 _（終了）
	×		=		×
C1		V1		C2		V2

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

NSC 74859501919-59-1S3I-201NSC74859NSC-74859STATInhibitorinhibitorinhibit

日本の代理先をお選びくださいナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
製品名			カスタマ需要量 *
お名前 *			タイトル
メールアドレス *			電話番号 *
デパートメント			組纖名 *
市区町村			都道府県
国或いは地域 *
必ず会社名を記載ください。個人への返信は行いません。
備考

製品名			Lot #
お名前 *			メールアドレス *
電話番号 *			部門 *
組纖名 *			国或いは地域 *
備考

NSC 74859 (Synonyms: S3I-201)

カスタマーレビュー

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

STAT アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NSC 74859 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

お名前
メール *

	Sorry, but the email address you supplied was invalid.

NSC 74859 (Synonyms: S3I-201)

カスタマーレビュー

NSC 74859 関連抗体

顧客検証

おすすめ

•関連スクリーニングライブラリ:

•関連小分子:

•関連タンパク質:

STAT アイソフォーム固有の製品をすべて表示:

生物活性

プロトコル

純度とドキュメンテーション

参考文献

カスタマーレビュー

NSC 74859 関連抗体

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

NSC 74859 Related Classifications

Molarity Calculator

Dilution Calculator

The molarity calculator equation

The dilution calculator equation

Keywords:

最近チェックした製品:

カスタマーレビュー

Request for HNMR Report

Request for HNMR Report